Company / Operating Income
Arbutus Biopharma Corp Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$38.2M
FY2025
5-year range
-$78.1M / -$38.2M
FY2021-FY2025
Trend
+50.0%
vs FY2024
Sector context
#68 of 204
Health Care
What the data says
At -$38M, Arbutus Biopharma Corp's operating income ranks #68 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$492M in FY2016 to -$32M in FY2019.
Based on SEC 10-K filings.
-$38M in FY2025.
Improved from -$78M to -$38M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#68 of 204 in Health CareTop 33% of 204This company -$38.2M Sector average $107.7M
▼
-135.4% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 50.0% year-over-year.
- Ranks #68 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$38.2M | +50.0% |
| FY2024 | -$76.3M | +2.3% |
| FY2023 | -$78.1M | -19.3% |
| FY2022 | -$65.5M | +11.0% |
| FY2021 | -$73.5M | +48.9% |
| FY2020 | -$143.9M | -343.8% |
| FY2019 | -$32.4M | +70.8% |
| FY2018 | -$110.9M | +0.0% |
| FY2017 | -$110.9M | +77.4% |
| FY2016 | -$491.6M | -373.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026